Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

1. Methylphenidate remains first-choice drug treatment for children and young people with ADHD

Methylphenidate remains first-choice drug treatment for children and young people with ADHD Methylphenidate remains first-choice drug treatment for children and young people with ADHD Discover Portal Discover Portal Methylphenidate remains first-choice drug treatment for children and young people with ADHD Published on 6 November 2018 doi: The stimulant methylphenidate has the best balance of effectiveness against side effects in children and young people with attention deficit hyperactivity (...) of bias. But this study supports NICE guidance on the range of potential drug options to consider in conjunction with behavioural and support strategies for children and young people with attention deficit hyperactivity disorder. Share your views on the research. Why was this study needed? Attention deficit hyperactivity disorder (ADHD) is a condition that starts in childhood. Symptoms include inattention, hyperactivity and impulsivity that occur at home and school, interfering with functioning

2019 NIHR Dissemination Centre

2. Cognitive behavioural therapy could benefit adults with attention deficit hyperactivity disorder (ADHD)

Cognitive behavioural therapy could benefit adults with attention deficit hyperactivity disorder (ADHD) Cognitive behavioural therapy could benefit adults with ADHD Discover Portal Discover Portal Cognitive behavioural therapy could benefit adults with attention deficit hyperactivity disorder (ADHD) Published on 21 August 2018 doi: Cognitive behavioural therapy improves the core symptoms of attention deficit hyperactivity disorder (ADHD) in adults, compared with a range of other treatments (...) used a variety of outcome measures, which made it difficult to compare the interventions. Despite these limitations, the review provides evidence that reinforces current guidance and practice. Share your views on the research. Why was this study needed? Attention deficit hyperactivity disorder (ADHD) is a group of behavioural symptoms which usually begin in childhood. While the symptoms of inattentiveness, hyperactivity and impulsiveness usually improve with age, they can continue into adulthood

2019 NIHR Dissemination Centre

3. Amphetamines probably the best first-choice treatment for adults with ADHD

Amphetamines probably the best first-choice treatment for adults with ADHD Amphetamines probably the best first-choice treatment for adults with ADHD Discover Portal Discover Portal Amphetamines probably the best first-choice treatment for adults with ADHD Published on 30 October 2018 doi: There is further evidence to support the amphetamines as the most effective group of drugs for treating adults with attention deficit hyperactivity disorder in the short-term. Two of these drugs were shown (...) a quarter of the studies having low risk of bias. The network meta-analysis allowed the authors to compare different drugs with each other as well as with placebos (dummy pills). It strengthens the evidence behind NICE guidelines which recommend a trial of either the amphetamine lisdexamfetamine or another stimulant, methylphenidate, as first-line treatments. Share your views on the research. Why was this study needed? Attention deficit hyperactivity disorder (ADHD) is a persistent pattern

2019 NIHR Dissemination Centre

4. Quick Guide, National clinical guideline for the assessment of ADHD in children and young people

Quick Guide, National clinical guideline for the assessment of ADHD in children and young people National clinical guideline for assessment and treatment of ADHD in children and young people published by the Danish Health Authority Authority, November 2018 It was not considered necessary to update the recommendation in 2018. Professional observers are independent persons who have in-depth knowledge of both children's normal behaviour and development and of ADHD, and who take a multidisciplinary (...) approach to ADHD in their daily work. The observation must be geared to the specific problem with the child in question. It was not considered necessary to update the recommendation in 2018. It is recommended that young people with ADHD follow the Danish Veterinary and Food A d m i n i s t r a t i o n ’ s dietary advice – likewise all other children and young people. The recommendation was updated without amendments in 2018. It is recommended that young people with ADHD follow the Danish Veterinary

2019 Danish National Clinical Guidelines

5. ADHD in children and youth: Part 3?Assessment and treatment with comorbid ASD, ID, or prematurity

ADHD in children and youth: Part 3?Assessment and treatment with comorbid ASD, ID, or prematurity Attention-deficit hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder. Three position statements have been developed by the Canadian Paediatric Society, following systematic literature reviews. Statement objectives are to: 1) Summarize the current clinical evidence regarding ADHD, 2) Establish a standard for ADHD care, and 3) Assist Canadian clinicians in making well-informed (...) , evidence-based decisions to enhance care of children and youth with this condition. Specific topics reviewed in Part 3, which focuses on associated autism spectrum disorder, intellectual disability, and prematurity, include the challenges of diagnostic assessment, common presentations, the role of genetics, and treatment, including the benefits of physical activity. Recommendations are based on current guidelines, evidence from the literature, and expert consensus. Keywords: Autism; ADHD; Intellectual

2018 Canadian Paediatric Society

6. ADHD in children and youth: Part 2?Treatment

ADHD in children and youth: Part 2?Treatment Attention-deficit hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder. Three position statements have been developed by the Canadian Paediatric Society, following systematic literature reviews. Statement objectives are to: 1) Summarize the current clinical evidence regarding ADHD, 2) Establish a standard for ADHD care, and 3) Assist Canadian clinicians in making well-informed, evidence-based decisions to enhance care of children (...) the literature, and expert consensus. Keywords: ADHD; Adverse effects; Combined interventions; Medication management

2018 Canadian Paediatric Society

7. ADHD in children and youth: Part 1?Etiology, diagnosis, and comorbidity

ADHD in children and youth: Part 1?Etiology, diagnosis, and comorbidity Attention-deficit hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder. Three position statements have been developed by the Canadian Paediatric Society, following systematic literature reviews. Statement objectives are to: 1) Summarize the current clinical evidence regarding ADHD, 2) Establish a standard for ADHD care, and 3) Assist Canadian clinicians in making well-informed, evidence-based decisions (...) Guidelines Network, and the Eunethydis European ADHD Guidelines Group, were reviewed. Because ADHD is a heterogeneous disorder, comprehensive medical assessment for ADHD should always include a complete history, a physical examination, and a thorough consideration of differential diagnosis and related comorbidities. Specific recommendations for information gathering, testing, and referral are offered. Keywords: Attention-deficit hyperactivity disorder; Comorbidity; Diagnosis; Etiology

2018 Canadian Paediatric Society

8. Nutritional or dietary interventions for children and adolescents with autism spectrum disorder or ADHD

Nutritional or dietary interventions for children and adolescents with autism spectrum disorder or ADHD Nutritional or dietary interventions for children and adolescents with autism spectrum disorder or ADHD We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Nutritional or dietary interventions for children and adolescents with autism spectrum (...) disorder or ADHD Share: Reading time approx. 6 minutes There are theories that different types of nutritional or dietary interventions, where specific food items are excluded from the diet or where nutritional supplements are added, may affect the symptoms of persons with Attention Deficit Hyperactivity Disorder (ADHD) or autism spectrum disorder. This applies, for example, to gluten-free and casein-free diet, ketogenic diet (a strict option of a low carbohydrate diet) or diet where sugar or various

2018 Swedish Council on Technology Assessement

9. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. (PubMed)

Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Attention deficit hyperactivity disorder (ADHD) is a childhood-onset disorder characterised by inattention, hyperactivity, and impulsivity. ADHD can persist into adulthood and can affects individuals' social and occupational functioning, as well as their quality of life and health. ADHD is frequently associated with other mental disorders such as substance use disorders and anxiety and affective disorders. Amphetamines (...) are used to treat adults with ADHD, but uncertainties about their efficacy and safety remain.To examine the efficacy and safety of amphetamines for adults with ADHD.In August 2017, we searched CENTRAL, MEDLINE, Embase, PsycINFO, 10 other databases, and two trials registers, and we ran citation searches for included studies. We also contacted the corresponding authors of all included studies, other experts in the field, and the pharmaceutical company, Shire, and we searched the reference lists

2018 Cochrane

10. ADHD

ADHD Top results for adhd - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for adhd The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

11. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. (PubMed)

Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. This is an update of the original Cochrane Review published in Issue 4, 2011.Attention deficit hyperactivity disorder (ADHD) is the most prevalent of the comorbid psychiatric disorders that complicate tic disorders. Medications commonly used to treat ADHD symptoms include stimulants such as methylphenidate and amphetamine; non-stimulants, such as atomoxetine; tricyclic (...) antidepressants; and alpha agonists. Alpha agonists are also used as a treatment for tics. Due to the impact of ADHD symptoms on the child with tic disorder, treatment of ADHD is often of greater priority than the medical management of tics. However, for many decades, clinicians have been reluctant to use stimulants to treat children with ADHD and tics for fear of worsening their tics.  OBJECTIVES: To assess the effects of pharmacological treatments for ADHD in children with comorbid tic disorders on symptoms

2018 Cochrane

12. Stimulants for ADHD in children: Revisited

Stimulants for ADHD in children: Revisited Stimulants for ADHD in children: Revisited January - February 2018 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 110 T his Letter reviews our previous publications and research on this topic and explores whether our publications have led (...) to a change in prescribing of stimulants to children in BC. Despite concerns, stimulant drug treatment of childhood at- tention-deficit/hyperactivity disorder (ADHD) has increased worldwide over the last two decades. 1 The optimal manage- ment of this behavioral condition remains unknown and this is reflected in the wide variation of stimulant treatment by country, jurisdiction, income, race and ethnicity. 1,2 Children are particularly vulnerable to harms of long- term drug therapies and there should

2018 Therapeutics Letter

13. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. (PubMed)

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude (...) of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non-serious adverse events.To assess the adverse events associated with methylphenidate treatment for children and adolescents with ADHD in non-randomised studies.In January 2016, we searched CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, 12 other databases

2018 Cochrane

14. Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. (PubMed)

Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. Attention deficit hyperactivity disorder (ADHD) is a developmental condition characterised by symptoms of inattention, hyperactivity and impulsivity, along with deficits in executive function, emotional regulation and motivation. The persistence of ADHD in adulthood is a serious clinical problem.ADHD significantly affects social interactions, study and employment performance.Previous studies (...) suggest that cognitive-behavioural therapy (CBT) could be effective in treating adults with ADHD, especially when combined with pharmacological treatment. CBT aims to change the thoughts and behaviours that reinforce harmful effects of the disorder by teaching people techniques to control the core symptoms. CBT also aims to help people cope with emotions, such as anxiety and depression, and to improve self-esteem.To assess the effects of cognitive-behavioural-based therapy for ADHD in adults.In June

2018 Cochrane

15. Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling? (PubMed)

Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling? Among US adults, utilization of pharmacotherapy for attention-deficit hyperactivity disorder (ADHD) has increased more than ninefold since 1995-1996. Potential contraindications to ADHD pharmacotherapy include serious cardiovascular disease (CVD) and, for stimulants, addictions and bipolar disorder (BPD).To assess the prevalence (...) of potential contraindications among adults treated with ADHD pharmacotherapy.A retrospective cohort analysis was performed using the Truven Health MarketScan® database. Subjects filled ≥ 1 prescription for atomoxetine or ≥ 1 stimulant in 2014-2015, were aged 18-64 years, commercially insured throughout observation, and diagnosed with ADHD on two or more medical claims. Diagnoses and medical procedures were measured in the 12 months prior to pharmacotherapy initiation. Metrics included serious CVD

Full Text available with Trip Pro

2018 Drugs - real world outcomes

16. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. (PubMed)

Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Attention deficit hyperactivity disorder (ADHD) is a prevalent neurobiological condition, characterised by behavioral and cognitive symptoms such as inattention, impulsivity and/or excessive activity. The syndrome is commonly accompanied by psychiatric comorbidities and is associated with educational and occupational underachievement.Although psychostimulant medications are the mainstay of treatment for ADHD, not all (...) adults respond optimally to, or can tolerate, these medicines. Thus, alternative non-stimulant treatment approaches for ADHD have been explored. One of these alternatives is bupropion, an aminoketone antidepressant and non-competitive antagonism of nicotinic acetylcholine receptors. Bupropion is registered for the treatment of depression and smoking cessation, but is also used off-label to treat ADHD.To assess the effects and safety of bupropion for the treatment of adults with ADHD.We searched

Full Text available with Trip Pro

2017 Cochrane

17. Attention deficit hyperactivity disorder (ADHD): avoid guanfacine

Attention deficit hyperactivity disorder (ADHD): avoid guanfacine Prescrire IN ENGLISH - Spotlight ''Attention deficit hyperactivity disorder (ADHD): avoid guanfacine'', 1 October 2017 {1} {1} {1} | | > > > Attention deficit hyperactivity disorder (ADHD): avoid guanfacine Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Attention deficit (...) hyperactivity disorder (ADHD): avoid guanfacine In children diagnosed with attention deficit hyperactivity disorder (ADHD), guanfacine has no proven efficacy in improving family and social relationships. On the other hand, it has frequent, sometimes severe, adverse effects. In practice, it is best to avoid guanfacine. The diagnosis of attention deficit hyperactivity disorder in children is based on non-specific behavioural symptoms: inattentiveness, hyperactivity and impulsiveness. The disruptive impact

2017 Prescrire

18. Attentin (dexamfetamine) - attention deficit/hyperactivity disorder (ADHD)

Attentin (dexamfetamine) - attention deficit/hyperactivity disorder (ADHD) Attentin (dexamfetamine) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Attentin (dexamfetamine) Conclusion Attentin (dexamfetamine) is a CNS stimulant agent for treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years. Attentin can be used second-line when response to methylphenidate is not sufficiently effective or has caused (...) unacceptable adverse reactions. The indication for medicinal treatment of ADHD is made by a specialist in child and adolescent psychiatry upon which further treatment (maintenance treatment) may be decided by the general practitioner in collaboration with a child and adolescent psychiatrist (1). Pharmaceutical treatment should not be the only treatment for ADHD, but should be combined with non-pharmaceutical interventions (1). The effect of dexamfetamine on ADHD core symptoms in children and adults has

2017 Danish Pharmacotherapy Reviews

19. Intuniv (guanfacine) - ADHD

Intuniv (guanfacine) - ADHD Intuniv® (guanfacine) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Intuniv® (guanfacine) Conclusion With Intuniv (guanfacine), a new type of non-stimulant ADHD medication is introduced. Intuniv is approved for the treatment of ADHD in children and adolescents when central nervous stimulants are not suitable, not tolerated or have no effect. Thus, Intuniv has a more restrictive indication compared to the other non (...) -stimulant ADHD medicine, atomoxetine. Compared to placebo, Intuniv has an effect on ADHD core symptoms with medium effect size. It suggests that the effect of Intuniv is lower than that of methylphenidate, but comparable to or higher than that of atomoxetine. No convincing effect on functioning has been established. Adverse reactions and risks of interactions are significant and may be serious; especially sedation and somnolence are common and influence Intuniv's effect on ADHD core symptoms. Intuniv

2017 Danish Pharmacotherapy Reviews

20. ADHD Medication and Substance-Related Problems

ADHD Medication and Substance-Related Problems Substance use disorders are major contributors to excess mortality among individuals with attention deficit hyperactivity disorder (ADHD), yet associations between pharmacological ADHD treatment and substance-related problems remain unclear. This study investigated concurrent and long-term associations between ADHD medication treatment and substance-related events.The authors analyzed 2005-2014 commercial health care claims from 2,993,887 (47.2 (...) % female) adolescent and adult ADHD patients. Within-individual analyses compared the risk of substance-related events (i.e., emergency department visits related to substance use disorders) during months in which patients received prescribed stimulant medication or atomoxetine relative to the risk during months in which they did not.In adjusted within-individual comparisons, relative to periods in which patients did not receive ADHD medication, male patients had 35% lower odds of concurrent substance

2017 EvidenceUpdates